---
title: "Antengene presents strong clinical data update at JPM, focusing on next-gen ADCs and TCEs.SEHK:. Jan 15, 2026."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/272767505.md"
description: "On January 15, 2026, Antengene Corporation Limited (SEHK:, a top global biotech firm, based in Shanghai and Hong Kong, is committed to innovating and commercializing advanced medicines. Antengene focuses on developing and marketing cutting-edge drugs, striving to lead the way in the industry."
datetime: "2026-01-16T01:02:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272767505.md)
  - [en](https://longbridge.com/en/news/272767505.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272767505.md)
---

# Antengene presents strong clinical data update at JPM, focusing on next-gen ADCs and TCEs.SEHK:. Jan 15, 2026.

On January 15, 2026, Antengene Corporation Limited (SEHK: 6996.HK), a top global biotech firm, based in Shanghai and Hong Kong, is committed to innovating and commercializing advanced medicines. Antengene focuses on developing and marketing cutting-edge drugs, striving to lead the way in the industry.

### Related Stocks

- [06996.HK](https://longbridge.com/en/quote/06996.HK.md)

## Related News & Research

- [Antengene Showcases Pipeline Progress at J.P. Morgan Healthcare Conference](https://longbridge.com/en/news/272765330.md)
- [Laekna Says Cancer Drug Meets Progression-free Survival Goal in Phase 3 Trial](https://longbridge.com/en/news/282783180.md)
- [Hengrui Pharmaceuticals Unit Gets Approval for Heart Failure Drug Trial](https://longbridge.com/en/news/282521960.md)
- [Novo Nordisk Partners with OpenAI to Boost Drug Development, Delivery](https://longbridge.com/en/news/282641629.md)
- [CSPC Pharmaceutical Gets China Nod for Clinical Trial of Tumor Drug](https://longbridge.com/en/news/282823913.md)